Tekla Capital Management LLC Invests $2.18 Million in Iqvia Holdings Inc (IQV)

Tekla Capital Management LLC acquired a new stake in Iqvia Holdings Inc (NYSE:IQV) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 16,800 shares of the medical research company’s stock, valued at approximately $2,180,000.

Several other institutional investors also recently made changes to their positions in the stock. Kornitzer Capital Management Inc. KS purchased a new position in shares of Iqvia in the 3rd quarter valued at approximately $35,062,000. GAM Holding AG raised its position in shares of Iqvia by 182.7% in the 3rd quarter. GAM Holding AG now owns 8,567 shares of the medical research company’s stock valued at $1,111,000 after purchasing an additional 5,537 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Iqvia by 309.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,803 shares of the medical research company’s stock valued at $363,000 after purchasing an additional 2,118 shares during the last quarter. First Foundation Advisors purchased a new position in Iqvia during the 3rd quarter worth approximately $340,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Iqvia by 25.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 183,011 shares of the medical research company’s stock worth $23,744,000 after buying an additional 37,239 shares during the last quarter. 89.33% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have issued reports on IQV. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $142.00 price target for the company in a research report on Tuesday, October 23rd. Morgan Stanley raised their price target on shares of Iqvia from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Monday. Piper Jaffray Companies raised their price target on shares of Iqvia to $131.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 23rd. Wells Fargo & Co raised their price target on shares of Iqvia from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Monday, August 13th. Finally, Barclays raised their price target on shares of Iqvia from $130.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 23rd. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and an average target price of $134.41.

In other news, Director John G. Danhakl sold 370,470 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total transaction of $46,245,770.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin C. Knightly sold 9,216 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $126.46, for a total transaction of $1,165,455.36. The disclosure for this sale can be found here. Insiders have sold a total of 601,586 shares of company stock worth $75,510,422 in the last ninety days. Corporate insiders own 6.00% of the company’s stock.

Shares of NYSE IQV opened at $127.32 on Tuesday. The company has a market cap of $25.30 billion, a PE ratio of 29.20, a PEG ratio of 1.79 and a beta of 0.81. Iqvia Holdings Inc has a 12 month low of $91.57 and a 12 month high of $135.48. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.03. The business had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The business’s revenue was up 5.2% compared to the same quarter last year. As a group, analysts forecast that Iqvia Holdings Inc will post 5.13 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Tekla Capital Management LLC Invests $2.18 Million in Iqvia Holdings Inc (IQV)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2018/12/04/tekla-capital-management-llc-invests-2-18-million-in-iqvia-holdings-inc-iqv.html.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Article: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit